Application of Dynamic Light Scattering (DLS) to Protein Therapeutic Formulations: Principles, Measurements and Analysis - 1. Basic Principles
White Paper Nov 19, 2014
Malvern Panalytical
Dynamic light scattering (DLS) is an analytical technique used to measure the
particle size distribution of protein formulations across the oligomer and sub-micron
size ranges of approximately 1 nm to 1 μm. The popularity of DLS within the
biopharmaceutical industry is a consequence of the technique’s wide working size and
extended sample concentration ranges, as well as its low volume requirements. With
that said, the challenge that remains with the application of DLS to protein therapeutic
formulations is centered around data interpretation. This four-part white paper series
examines common issues and questions surrounding the principles, measurements
and analysis of DLS data and discusses how to minimize the time required for and
increase the accuracy of acquiring and interpreting DLS data during the biotherapeutic
development process. Here, in Part One of this series, we provide an overview of the
key principles of DLS: theory, correlation statistics, deconvolution algorithms, and the
intensity to mass transform.
Related White Papers
One of the common molecular analyses is the determination of a lead molecule’s binding kinetics and affinity to the target. This warrants the need for analytical instruments capable of characterizing such molecules. Download this whitepaper to discover an approach that accurately measures multiple high-affinity interactions over long run times.
READ MOREData accessibility has been a challenge because the lab operator’s relationship to data is usually prescribed by preset LIMS features. Using data science algorithms, it is now possible to process and integrate all LIMS and enterprise data to provide valuable insights and timely, meaningful recommendations. Access this whitepaper to discover a technology that provides a holistic view of your data, delivers statistical and business analysis and increases productivity.
Neutralizing antibodies are currently being investigated as one such strategy against SARS-CoV-2, as they have the potential to block the virus from infecting host cells. Download this whitepaper to learn more about the antiviral mechanism of SARS-CoV-2 neutralizing antibodies and global efforts to develop neutralizing antibody products against the virus.
READ MORELike what you just read? You can find similar content on the communities below.
Analysis & Separations Biopharma Proteomics & MetabolomicsTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
